Loading...
XTAI
3054
Market cap60mUSD
Dec 05, Last price  
23.60TWD
1D
-0.84%
1Q
-0.21%
Jan 2017
-18.41%
IPO
-89.46%
Name

LIWANLI Innovation Co Ltd

Chart & Performance

D1W1MN
XTAI:3054 chart
P/E
—
P/S
19.20
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.67%
Rev. gr., 5y
-5.24%
Revenues
99m
+154.98%
1,243,110,0001,019,155,0002,317,240,0002,736,562,0002,443,691,0002,235,930,000834,909,000323,097,000348,213,000185,512,000129,782,000276,879,00047,813,00033,988,00038,887,00099,156,000
Net income
-32m
L
86,816,000117,287,00035,782,000-58,152,000289,775,00015,304,000-103,453,00062,796,00081,910,000891,0002,782,000-13,613,00045,563,000-120,907,0005,103,000-32,074,000
CFO
14m
P
89,430,00078,412,000-157,772,000-104,023,000-89,820,000473,038,00034,044,000112,684,00096,034,000-123,090,000-109,160,000-36,627,000-61,133,00078,479,000-50,343,00014,202,000
Dividend
Jun 28, 20180.4 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

LIWANLI Innovation Co., Ltd. operates in the biomedical science industry. It provides products in the areas of nutrition and healthcare. The company offers Vigoway and powder collection products for male, female, elderly, and children audience. Its products include probiotic enzymes, pro-active nutrients, resveratrol red grape extract, algae DHA soft gels, shea butter with type II collagen soft gels, algae astaxanthin Q10 soft gels, cordyceps militaries powder, tooth guard tablets, bovine and goat's milk bites, bilberry-tablets, DHA and vitamin D3 drops, and other products. The company was formerly known as Carry Technology International Co., Ltd. and changed its name to LIWANLI Innovation Co., Ltd. in 2015. LIWANLI Innovation Co., Ltd. was founded in 1980 and is based in New Taipei City, Taiwan.
URL
http://www.carry.com.tw
IPO date
Jul 22, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT